A new study from the Avon Longitudinal Study of Parents and Children (ALSPAC) is challenging long-held assumptions about how we measure overweight and obesity in children. According to findings published in Obesity and Endocrinology in January 2025, body mass index (BMI) — the most commonly used tool for assessing weight status — may dramatically overestimate...
Endocrine Society champions resolution passed by House of Delegates On June 10, the American Medical Association (AMA) House of Delegates passed the Endocrine Society’s resolution to improve access to anti-obesity medications. In the resolution, the AMA committed to advocating for reducing the burden of prior authorization, when healthcare providers must seek insurance plan approval before...
Redefining Roles and Mechanisms of Obesity Treatment at ENDO 2025 Endocrine News talks with the chair and presenters of “Bariatric Surgery and Emerging Medications: Redefining Roles and Mechanisms,”an ENDO 2025 session that analyzes a variety of factors that are impacted by bariatric surgery including postsurgical hypoglycemia, surgery versus pharmacological solutions, as well as a number...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist On June 2, Regeneron Pharmaceuticals, Inc., announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the...
The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate. The legislation will ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications. Medicare coverage of anti-obesity medications is currently prohibited under law. Access to these medications would benefit millions of Americans. More than...
Salivary cortisol and cortisone can be valuable tools in diagnosing adrenal insufficiency (AI), offering non-invasive options for screening and potentially avoiding the need for ACTH stimulation tests in some cases, states a recent study in The Journal of Clinical Endocrinology and Metabolism. Adrenal insufficiency (AI), such as in cases of Addison’s disease and Congenital Adrenal Hyperplasia,...
Endocrine-disrupting chemicals have been implicated in a wide range of poor health outcomes, including infertility and obesity. Endocrine News speaks to Almudena Veiga-Lopez, DVM, PhD, the chair of an upcoming ENDO 2025 symposium on these chemicals’ effects on reproductive organs, which are particularly vulnerable to EDCs. Endocrine-disrupting chemicals are everywhere, and there is seemingly no...
As I come to the end of my term at ENDO 2025 next month in San Francisco, Calif., I can look back with great pride at what the Endocrine Society has accomplished over the past 12 months. My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial...
Endocrine-disrupting chemicals have been implicated in a wide range of poor health outcomes, including infertility and obesity. Endocrine News speaks to Almudena Veiga-Lopez, DVM, PhD, the chair of an upcoming ENDO 2025 symposium on these chemicals’ effects on reproductive organs, which are particularly vulnerable to EDCs. Endocrine-disrupting chemicals are everywhere, and there is seemingly no...
As I come to the end of my term at ENDO 2025 next month in San Francisco, Calif., I can look back with great pride at what the Endocrine Society has accomplished over the past 12 months. My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial...
